메뉴 건너뛰기




Volumn 31, Issue 6, 2008, Pages 1171-1176

Impact of renin-angiotensin system inhibition on microalbuminuria in type 2 diabetes: A post Hoc analysis of the Shiga Microalbuminuria Reduction Trial (SMART)

(33)  Uzu, Takashi a   Sawaguchi, Makoto a   Maegawa, Hiroshi a   Kashiwagi, Atsunori a   Tomita, Koubin b   Horide, Naoki c   Kawabata, Toshihiro d   Nishio, Yoshihiko a   Ugi, Satoshi a   Sekine, Osamu a   Sugimoto, Toshiro a   Araki, Shin Ichi a   Isshiki, Keiji a   Nishimura, Masataka e   Shimizu, Shinya e   Yamada, Shyu f   Kida, Yasuo g   Hashimoto, Tetsuya g   Takahara, Noriko h   Egawa, Katuya i   more..


Author keywords

Blood pressure; Diabetic nephropathy; Microalbuminuria; Renin angiotensin system

Indexed keywords

ALBUMIN; AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IMIDAPRIL; LISINOPRIL; TEMOCAPRIL; TRANDOLAPRIL; VALSARTAN;

EID: 48349136426     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.1171     Document Type: Article
Times cited : (10)

References (24)
  • 1
    • 0035922444 scopus 로고    scopus 로고
    • The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
    • Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group
    • Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878.
    • (2001) N Engl J Med , vol.345 , pp. 870-878
    • Parving, H.H.1    Lehnert, H.2    Brochner-Mortensen, J.3    Gomis, R.4    Andersen, S.5    Arner, P.6
  • 2
    • 0035922441 scopus 로고    scopus 로고
    • Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    • Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
    • (2001) N Engl J Med , vol.345 , pp. 861-869
    • Brenner, B.M.1    Cooper, M.E.2    de Zeeuw, D.3
  • 3
    • 0037031270 scopus 로고    scopus 로고
    • Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect
    • MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators
    • Viberti G, Wheeldon NM, MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672-678.
    • (2002) Circulation , vol.106 , pp. 672-678
    • Viberti, G.1    Wheeldon, N.M.2
  • 4
    • 0141789624 scopus 로고    scopus 로고
    • Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis
    • Jafar TH, Stark PC, Schmid CH, et al: Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139: 244-253.
    • (2003) Ann Intern Med , vol.139 , pp. 244-253
    • Jafar, T.H.1    Stark, P.C.2    Schmid, C.H.3
  • 5
    • 0038460302 scopus 로고    scopus 로고
    • The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report
    • Chobanian AV, Bakris GL, Black HR, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
    • (2003) JAMA , vol.289 , pp. 2560-2572
    • Chobanian, A.V.1    Bakris, G.L.2    Black, H.R.3
  • 6
    • 34548383480 scopus 로고    scopus 로고
    • ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension
    • Mancia G, De Backer G, Dominiczak A, et al: 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25: 1751-1762.
    • (2007) J Hypertens , vol.2007 , Issue.25 , pp. 1751-1762
    • Mancia, G.1    De Backer, G.2    Dominiczak, A.3
  • 7
    • 34249905442 scopus 로고    scopus 로고
    • Reduction of microalbuminuria in patients with type 2 diabetes: The Shiga Microalbuminuria Reduction Trial (SMART)
    • Shiga Microalbuminuria Reduction Trial (SMART) Group
    • Shiga Microalbuminuria Reduction Trial (SMART) Group: Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care 2007; 30: 1581-1583.
    • (2007) Diabetes Care , vol.30 , pp. 1581-1583
  • 8
    • 0037431774 scopus 로고    scopus 로고
    • Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial
    • Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 117-124.
    • (2003) Lancet , vol.361 , pp. 117-124
    • Nakao, N.1    Yoshimura, A.2    Morita, H.3    Takada, M.4    Kayano, T.5    Ideura, T.6
  • 9
    • 0038185261 scopus 로고    scopus 로고
    • Effect of low-dose perindopril/indapamide on albuminuria in diabetes: Preterax in albuminuria regression: PREMIER
    • Mogensen CE, Viberti G, Halimi S, et al: Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension 2003; 41: 1063-1071.
    • (2003) Hypertension , vol.41 , pp. 1063-1071
    • Mogensen, C.E.1    Viberti, G.2    Halimi, S.3
  • 10
    • 0037213037 scopus 로고    scopus 로고
    • Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)
    • Adler AI, Stevens RJ, Manley SE, et al: Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-232.
    • (2003) Kidney Int , vol.63 , pp. 225-232
    • Adler, A.I.1    Stevens, R.J.2    Manley, S.E.3
  • 11
    • 1042302788 scopus 로고    scopus 로고
    • Nephropathy in diabetes
    • American Diabetes Association
    • American Diabetes Association: Nephropathy in diabetes. Diabetes Care 2004; 27(Suppl 1): S79-S83.
    • (2004) Diabetes Care , vol.27 , Issue.SUPPL. 1
  • 12
    • 0034700790 scopus 로고    scopus 로고
    • Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
    • Heart Outcomes Prevention Evaluation (HOPE) Study Investigators
    • Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
    • (2000) Lancet , vol.355 , pp. 253-259
  • 13
    • 0035948631 scopus 로고    scopus 로고
    • Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals
    • Gerstein HC, Mann JF, Yi Q, et al: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. J Am Med Assoc 2001; 286: 421-426.
    • (2001) J Am Med Assoc , vol.286 , pp. 421-426
    • Gerstein, H.C.1    Mann, J.F.2    Yi, Q.3
  • 14
    • 0035989568 scopus 로고    scopus 로고
    • Microalbuminuria: Marker of vascular dysfunction, risk factor for cardiovascular disease
    • Garg JP, Bakris GL: Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 2002; 7: 35-43.
    • (2002) Vasc Med , vol.7 , pp. 35-43
    • Garg, J.P.1    Bakris, G.L.2
  • 15
    • 34249746896 scopus 로고    scopus 로고
    • Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes
    • Araki S, Haneda M, Koya D, et al: Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes. Diabetes 2007; 56: 1727-1730.
    • (2007) Diabetes , vol.56 , pp. 1727-1730
    • Araki, S.1    Haneda, M.2    Koya, D.3
  • 16
    • 34248178511 scopus 로고    scopus 로고
    • Albiminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
    • Eijkelkamp WB, Zhang Z, Resmuzzi G, et al: Albiminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007; 18: 1540-1546.
    • (2007) J Am Soc Nephrol , vol.18 , pp. 1540-1546
    • Eijkelkamp, W.B.1    Zhang, Z.2    Resmuzzi, G.3
  • 17
    • 0036833657 scopus 로고    scopus 로고
    • Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: A randomized double-blind placebo-conrolled crossover study
    • Sasso FC, Carbonara O, Persico M, et al: Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-conrolled crossover study. Diabetes Care 2002; 25: 1909-1913.
    • (2002) Diabetes Care , vol.25 , pp. 1909-1913
    • Sasso, F.C.1    Carbonara, O.2    Persico, M.3
  • 18
    • 0042804810 scopus 로고    scopus 로고
    • Effect of losartan on micro-albuminuria in normotensive patients with type 2 diabetes mellitus. A randomized clinical trial
    • Zandbergen AA, Baggen Lamberg SW, Bootsma AH, de Zeeuw D, Ouwendijk RJ: Effect of losartan on micro-albuminuria in normotensive patients with type 2 diabetes mellitus. A randomized clinical trial. Ann Intern Med 2003; 139: 90-96.
    • (2003) Ann Intern Med , vol.139 , pp. 90-96
    • Zandbergen, A.A.1    Baggen Lamberg, S.W.2    Bootsma, A.H.3    de Zeeuw, D.4    Ouwendijk, R.J.5
  • 20
    • 0035964911 scopus 로고    scopus 로고
    • Differential expression of T- and L-type voltage-dependent calcium channels in renal resistance vessels
    • Haasen PB, Jensen BL, Andreansen D, Skott O: Differential expression of T- and L-type voltage-dependent calcium channels in renal resistance vessels. Circ Res 2001; 89: 630-638.
    • (2001) Circ Res , vol.89 , pp. 630-638
    • Haasen, P.B.1    Jensen, B.L.2    Andreansen, D.3    Skott, O.4
  • 21
    • 33745683627 scopus 로고    scopus 로고
    • Comparison between valsartan and valsartan plus calsidipine in type II diabetics with normo- microalbuminoria
    • Katayama K, Nomura S, Ishikawa H, et al: Comparison between valsartan and valsartan plus calsidipine in type II diabetics with normo- microalbuminoria. Kidney Int 2006; 70: 151-156.
    • (2006) Kidney Int , vol.70 , pp. 151-156
    • Katayama, K.1    Nomura, S.2    Ishikawa, H.3
  • 22
    • 36749047471 scopus 로고    scopus 로고
    • Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive with chronic renal disease
    • Fujita T, Ando K, Nishimura H, et al: Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive with chronic renal disease. Kidney Int 2007; 72: 1543-1549.
    • (2007) Kidney Int , vol.72 , pp. 1543-1549
    • Fujita, T.1    Ando, K.2    Nishimura, H.3
  • 23
    • 34548028268 scopus 로고    scopus 로고
    • Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis
    • Ishimitsu T, Kameda T, Akashiba A, et al: Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. Hypertens Res 2007; 30: 621-626.
    • (2007) Hypertens Res , vol.30 , pp. 621-626
    • Ishimitsu, T.1    Kameda, T.2    Akashiba, A.3
  • 24
    • 34249897487 scopus 로고    scopus 로고
    • Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: A randomized controlled study of benazepril and losactan in chronic renal insufficiency
    • Hou FF, Xie D, Zhang X, et al: Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losactan in chronic renal insufficiency. J Am Soc Nephrol 2007; 18: 1889-1898.
    • (2007) J Am Soc Nephrol , vol.18 , pp. 1889-1898
    • Hou, F.F.1    Xie, D.2    Zhang, X.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.